Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.

Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: A novel type of pyrrolopyrazole derivatives shown in general formula (I), a preparation method thereof and application thereof or a pharmaceutical composition containing same as a therapeutic agent, particularly as a gastric acid secretion inhibitor and a potassium-competitive acid blocker (P-CABs) in biomedicine.

Abstract: Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and the medical use thereof. In particular, disclosed are a novel class of pyrrolopyrazole derivatives represented by general formula (I), a preparation method therefor, and the use of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives in biomedicine as therapeutic agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blochers (P-CABs). The definitions of various substituent (R1, R2, R3, R4) and the group (X) in general formula (I) are the same as the definitions in the description.

Abstract: A class of pyrrolopyrazole derivatives represented by general formula (I), a preparation method thereof, and the applications of said derivatives or of pharmaceutical compositions containing said class of derivatives as therapeutic agents, especially the application as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs) in biomedicine.

Abstract: The present invention relates to pyrrolo-pyrazol derivatives, a preparation method thereof and application thereof in medicine, and particularly to a novel category of pyrrolo-pyrazol derivatives represented by formula (I), a preparation method thereof and a bio-pharmaceutical use thereof or of pharmaceutical compositions containing the same as therapeutic agents, especially as gastric acid secretion inhibitors and potassium-competitive acid blockers (P-CABs).

Abstract: The present invention relates to pyrrolo-pyrazol derivatives, a preparation method thereof and application thereof in medicine, and particularly to a novel category of pyrrolo-pyrazol derinatives respesented by formula (I), a preparation method thereof and a bio-pharmaceutical use thereof or of pharmaceutical compositions containing the same as therapeutic agents, especially as gastric acid secretion inhibitors and potassium-competitive acid blockers (P-CABs). Substituent groups (Ar and R1) in formula(I) are defined identically as in description.

Abstract: Methods for preparing synthetic heparins are provided. Synthetic heparin compounds, including ultralow molecular weight heparin compounds are provided. Also provided are methods of chemoenzymatically synthesizing structurally homogeneous ultra-low molecular weight heparins. Heparin compounds provided herein can have anticoagulant activity.

Abstract: Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.

Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine.

Abstract: The present invention provides a 2, 6-di-nitrogen-containing substituted purine derivative having a formula (I) structure, or pharmaceutical salt or hydrate thereof, and preparation method and use thereof. The compound is broad spectrum anticancer, low toxicity, high anticancer activity and good stability.

Abstract: The present invention provides a 2, 6-di-nitrogen-containing substituted purine derivative having a formula (I) structure, or pharmaceutical salt or hydrate thereof, and preparation method and use thereof. The compound is broad spectrum anticancer, low toxicity, high anticancer activity and good stability.

Abstract: Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine.

Abstract: A report generator of a storage area network management application includes a data validation mechanism that validates data related to managed resources operating in a storage area network. The data validation mechanism obtains first and second data sets concerning first and second characteristics of a resource operating in the storage area network and applies at least one data validation test using data sets to detect inconsistencies in data in the first and second data sets associated with the resource operating in the storage area network. Values can be compared in different columns of the same or different reports to detect report integrity errors or data mining errors. The report generator provides a storage area network management report based on data of the first data set and the second data set that accounts for inconsistencies in data associated with the resource as detected by the at least one data validation test.

Abstract: Methods for preparing synthetic heparins are provided. Synthetic heparin compounds, including ultralow molecular weight heparin compounds are provided. Also provided are methods of chemoenzymatically synthesizing structurally homogeneous ultra-low molecular weight heparins. Heparin compounds provided herein can have anticoagulant activity.

Abstract: A preparation method of original dye of Vat Brown R comprises the following steps: a. after acylation of 1,5-diaminoanthraquinone, 1-amino-5-benzamidoanthraquinone was prepared by acidic hydrolysis; b. 1-benzamido-4-bromoanthraquinone was obtained from 1-aminoanthraquinone by acylation and bromination; c. a condensate of Vat Brown R was obtained by condensation reaction of 1-amino-5-benzamidoanthraquinone and 1-benzamido-4-bromoanthraquinone; d. the original dye of Vat Brown R was obtained from the condensate of Vat Brown R by ring closing reaction and oxidation reaction. The method omits one oxidation step, economizes significant amount of oxidizing agent, and reduces significant amount of waste water, so it is very beneficial to environment protection; and the method also exhibited the advantages of highly increasing product yield and reducing the costs of raw materials to an extent of more than 30%.

Abstract: A Decision Support System (DSS) coalescer offloads and transforms data from an online statistical gathering database to a report query database adapted for report generation. The coalescer generates and populates a query database structured for query data retrieval, in contrast to realtime access transaction storage as in the online database. Configurations transform the online database into a star join schema (table structure) that centralizes database “facts” in a central table and forms associations to database “dimensions” upon which a query is likely to be based. The facts refer to items which tend to change regularly over time, such as sales volumes and unit shipped. Conversely, the dimensions include more static values such as time (e.g. days, weeks, and quarters) and geographic regions, such as states and countries. The resulting query model (schema) includes relatively small dimensions tables associated with (i.e. having a schema association to) a relatively larger fact table.